Home

John G Lemkey

CIK 1495904 · Chief Operating Officer · last filed 2020-12-02

John G Lemkey is a Chief Operating Officer who has filed 69 SEC Form 4 insider transactions across 1 company since 2018. The most recent filing shows the insider was granted $153 of ODT on Dec 2, 2020. Across all open-market trades the lifetime net is +$111.6M, making them a net buyer over the disclosed history. 29 SEC filings were submitted jointly with TANG CAPITAL MANAGEMENT LLC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

1

Total Filings

69

Lifetime Open-Market Net

$111.64M

Filer Profile

Reported Address
4747 EXECUTIVE DRIVE
SUITE 210
SAN DIEGO, CA 92121
Related Filers
TANG CAPITAL MANAGEMENT LLC — 29 joint filings, latest 2020-09-30
TANG CAPITAL PARTNERS LP — 29 joint filings, latest 2020-09-30
KEVIN TANG — 29 joint filings, latest 2020-09-30
Michael S Hearne — 12 joint filings, latest 2020-09-30
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Odonate Therapeutics, Inc. (ODT) Delisted Chief Operating Officer 15,242,239 $1.12 $17.07M $111.64M 69 2020-12-02

Recent Filings

69 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2020-12-02 Odonate Therapeutics, Inc. (ODT) Delisted Grant (A) +12 $153 EDGAR
2020-11-17 Odonate Therapeutics, Inc. (ODT) Delisted Grant (A) +96 $1.2K EDGAR
2020-11-03 Odonate Therapeutics, Inc. (ODT) Delisted Grant (A) +96 $1.2K EDGAR
2020-10-19 Odonate Therapeutics, Inc. (ODT) Delisted Grant (A) +88 $1.2K EDGAR
2020-10-02 Odonate Therapeutics, Inc. (ODT) Delisted Grant (A) +102 $1.2K EDGAR
2020-09-17 Odonate Therapeutics, Inc. (ODT) Delisted Grant (A) +90 $1.2K EDGAR
2020-09-02 Odonate Therapeutics, Inc. (ODT) Delisted Grant (A) +87 $1.2K EDGAR
2020-08-18 Odonate Therapeutics, Inc. (ODT) Delisted Grant (A) +38 $1.2K EDGAR
2020-08-04 Odonate Therapeutics, Inc. (ODT) Delisted Grant (A) +38 $1.2K EDGAR
2020-07-17 Odonate Therapeutics, Inc. (ODT) Delisted Grant (A) +33 $1.2K EDGAR
Showing 1–10 of 69
Page 1 of 7
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.